New drug aims to calm painful skin flares in hidradenitis suppurativa

NCT ID NCT06895499

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called HB0043 in 15 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. The drug is a bispecific antibody that targets two inflammatory proteins (IL-17A and IL-36R) to reduce inflammation. The main goal is to check safety and tolerability, with a secondary focus on whether it can reduce skin lesions by at least 50% after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HB0043 (a bispecific antibody targeting IL-17A and IL-36R)
What this could lead to
If successful, this could lead to a new treatment option that reduces painful skin abscesses and inflammation in people with hidradenitis suppurativa.
What could go wrong
This is an early-phase trial with only 15 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dermatology Hospital affiliated to Shandong First Medical University

    RECRUITING

    Jinan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.